Actively Recruiting
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Led by National Heart, Lung, and Blood Institute (NHLBI) · Updated on 2026-05-05
135
Participants Needed
1
Research Sites
214 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Background: Bruton s tyrosine kinase inhibitors (BTKi) are used to treat a form of leukemia. But taking BTKi can also increase a person s risk of developing an abnormal heart rhythm. This can cause sudden death. In this natural history study, researchers want to learn how BTKi affects the heart. Objective: To identify and monitor the effects of BTKi on the heart. Eligibility: People aged 18 and older currently receiving or planning to receive BTKi or venetoclax. Design: Participants who have not yet started BTKi will have 2 required clinic visits: 1 before they start taking BTKi, and 1 about 6 months later. Participants who are already taking BTKi will have 1 required visit. Participants will undergo multiple tests: A physical exam, including collection of blood and saliva. A test that measures heart activity via stickers placed on the chest. A test that uses sound waves to capture images of the heart. An exercise stress test that monitors heart activity and blood pressure while the participant works on a treadmill or stationary bike. Sound wave images of the heart may also be taken while the participant exercises. Stress magnetic resonance imaging (MRI) may be done in place of an exercise test. Participants will lie on a table that slides into a tube. They will be given drugs to stress the heart while images are taken. Participants may wear a device to monitor their heart at home. Participants may have repeat visits if they develop heart symptoms or if they need to stop taking BTKi. They will have follow-up phone calls each year for up to 3 years. ...
CONDITIONS
Official Title
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Currently receiving or planning to receive a BTKi or venetoclax
- Male or female, aged 18 or older
- Willing to comply with all study procedures and available for the study duration
- Able to understand and willing to sign informed consent
You will not qualify if you...
- Any acute cardiac condition including heart attack or decompensated heart failure within the past 3 months
- Pregnancy or breastfeeding, as BTK inhibitors are not recommended for pregnant or nursing individuals
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892
Actively Recruiting
Research Team
I
Ingrid C Frey
CONTACT
C
Christine E Gruessner, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here